WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014207232) ANTISENSE OLIGOMERS AND CONJUGATES TARGETING PCSK9
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/207232    International Application No.:    PCT/EP2014/063757
Publication Date: 31.12.2014 International Filing Date: 27.06.2014
IPC:
C12N 15/113 (2010.01), A61K 31/712 (2006.01), A61P 3/06 (2006.01)
Applicants: ROCHE INNOVATION CENTER COPENHAGEN A/S [DK/DK]; Fremtidsvej 3 DK-2970 Hørsholm (DK)
Inventors: ALBÆK, Nanna; (DK).
HEDTJÄRN, Maj; (DK).
LINDHOLM, Marie; (SE).
NIELSEN, Niels Fisker; (DK).
PETRI, Andreas; (DK).
RAVN, Jacob; (DK)
Priority Data:
13174092.0 27.06.2013 EP
13192930.9 14.11.2013 EP
13192938.2 14.11.2013 EP
PCT/EP2013/073858 14.11.2013 EP
14153253.1 30.01.2014 EP
14168331.8 14.05.2014 EP
Title (EN) ANTISENSE OLIGOMERS AND CONJUGATES TARGETING PCSK9
(FR) OLIGOMÈRES ANTISENS ET CONJUGUÉS CIBLANT PCSK9
Abstract: front page image
(EN)The present invention relates to oligomeric compounds and conjugates thereof that target Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) PCSK9 mRNA in a cell, leading to reduced expression of PCSK9. Reduction of PCSK9 expression is beneficial for a range of medical disorders, such as hypercholesterolemia and related disorders.
(FR)La présente invention concerne des composés oligomères et des conjugués de ceux-ci qui ciblent la proprotéine convertase subtilisine/kexine de type 9 (PCSK9) l'ARNm PCSK9 dans une cellule, conduisant à une expression réduite de PCSK9. La réduction de l'expression de PCSK9 est bénéfique pour le traitement de certains troubles médicaux, tels que l'hypercholestérolémie et des troubles associés.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)